At present, two anti-BCMA-directed CAR-T products are FDA approved for the treatment of extensively pretreated patients with r/r multiple myeloma after four or more prior therapies, namely ide-cel (idecabtagene vicleucel, bb2121, Abecma) and cilta-cel (ciltacabtagene autoleucel, LCAR-B38M, JNJ-4528, JNJ-68284528) [2,3]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.